Evidence map›Paper›PMID 39976600›Full record

ArticleThe Journal of experimental medicine2025

HMCN1 variants aggravate epidermolysis bullosa simplex phenotype.

Shir Bergson, Ofer Sarig, Moshe Giladi, Janan Mohamad, Mariana Mogezel-Salem, Karina Smorodinsky-Atias, Ofir Sade, Bar Manori, Sari Assaf, Kiril Malovitski and 17 more

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Shir Bergson *Division of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel.ORCID 0000-0002-7197-8837
Ofer Sarig *Division of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel.ORCID 0000-0003-2987-2091
Moshe GiladiFaculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0002-8589-6920
Janan MohamadDivision of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel.ORCID 0000-0002-9849-7566
Mariana Mogezel-SalemFaculty of Life Sciences, School of Neurobiology, Biochemistry and Biophysics, Tel Aviv University, Tel Aviv, Israel.ORCID 0009-0005-7277-2354
Karina Smorodinsky-AtiasFaculty of Life Sciences, School of Neurobiology, Biochemistry and Biophysics, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0002-5952-2650
Ofir SadeFaculty of Life Sciences, School of Neurobiology, Biochemistry and Biophysics, Tel Aviv University, Tel Aviv, Israel.ORCID 0009-0004-5849-782X
Bar ManoriFaculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0003-1414-0939
Sari AssafDivision of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel.ORCID 0000-0002-5574-4918
Kiril MalovitskiDivision of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel.ORCID 0000-0002-4171-6668
Yarden FellerDivision of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel.ORCID 0000-0002-0299-3304
Mor PavlovskyDivision of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel.ORCID 0009-0002-9881-0484
Stefan HainzlDepartment of Dermatology and Allergology, EB House Austria, Research Program for Molecular Therapy of Genodermatoses, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria.ORCID 0000-0001-6542-0039
Thomas KocherDepartment of Dermatology and Allergology, EB House Austria, Research Program for Molecular Therapy of Genodermatoses, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria.ORCID 0000-0002-3424-3049
Julia I HummelDepartment of Dermatology and Allergology, EB House Austria, Research Program for Molecular Therapy of Genodermatoses, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria.ORCID 0000-0002-8305-6135
Noy Eretz KdoshaDivision of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel.ORCID 0009-0000-7078-6086
Lubna Gazi KhairDivision of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel.ORCID 0009-0005-3987-7461
Roland ZaunerDepartment of Dermatology and Allergology, EB House Austria, Research Program for Molecular Therapy of Genodermatoses, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria.ORCID 0000-0003-0590-3877
Josefina Pinon HofbauerDepartment of Dermatology and Allergology, EB House Austria, Research Program for Molecular Therapy of Genodermatoses, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria.ORCID 0000-0002-8558-9031
Ruby Shalom-FeuersteinThe Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.ORCID 0000-0002-8016-2290
Verena WallyDepartment of Dermatology and Allergology, EB House Austria, Research Program for Molecular Therapy of Genodermatoses, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria.ORCID 0000-0001-8705-3890
Ulrich KollerDepartment of Dermatology and Allergology, EB House Austria, Research Program for Molecular Therapy of Genodermatoses, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria.ORCID 0000-0002-6285-1789
Liat SamuelovDivision of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel.ORCID 0009-0009-6498-9755
Yoni HaitinFaculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0002-1648-6792
Uri AsheryFaculty of Life Sciences, School of Neurobiology, Biochemistry and Biophysics, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0001-6338-7888
Rotem RubinsteinFaculty of Life Sciences, School of Neurobiology, Biochemistry and Biophysics, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0003-3657-5984
Eli SprecherDivision of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel.ORCID 0000-0002-4093-1032

Funding

Austrian Science Fund I4754-BDEBRA International APR_2020-06Israel Ministry of Science Technology 3-17373Israel Science Foundation 2830/20Paracelsus Medical University Salzburg PMU-RIF 2021-UP-001-Wally
6 · The paper itself

Abstract

Epidermolysis bullosa simplex (EBS) refers to a heterogeneous group of inherited skin disorders characterized by blister formation within the basal cell layer. The disease is characterized by marked variations in phenotype severity, suggesting co-inheritance of genetic modifiers. We identified three deleterious variants in HMCN1 that co-segregated with a more severe phenotype in a group of 20 individuals with EBS caused by mutations in KRT14, encoding keratin 14 (K14). HMCN1 codes for hemicentin-1. Protein modeling, molecular dynamics simulations, and functional experiments showed that all three HMCN1 variants disrupt protein stability. Hemicentin-1 was found to be expressed in human skin above the BMZ. Using yeast-2-hybrid, co-immunoprecipitation, and proximity ligation assays, we found that hemicentin-1 binds K14. Three-dimensional skin equivalents grown from hemicentin-1-deficient cells were found to spontaneously develop subepidermal blisters, and HMCN1 downregulation was found to reduce keratin intermediate filament formation. In conclusion, hemicentin-1 binds K14 and contributes to BMZ stability, which explains the fact that deleterious HMCN1 variants co-segregate with a more severe phenotype in KRT14-associated EBS.

Indexed as

Epidermolysis Bullosa SimplexAdolescentChildFemaleHumansKeratin-14MaleMutationPhenotypeProtein BindingProtein StabilitySkinKeratin-14KRT14 protein, human

Identifiers

PMID39976600
PMCPMC11841684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.